Your browser doesn't support javascript.
loading
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.
Kelly, Wm Kevin; Marks, Paul; Richon, Victoria M.
Affiliation
  • Kelly WK; Division of Solid Tumor Oncology, Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center at Thomas Jefferson University. wm.kevin.kelly@jefferson.edu.
  • Marks P; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Richon VM; Discovery and Preclinical Sciences, Sanofi Oncology, Cambridge, Massachusetts.
Clin Cancer Res ; 21(10): 2198-200, 2015 May 15.
Article in En | MEDLINE | ID: mdl-25979925
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Histone Deacetylase Inhibitors / Hydroxamic Acids Limits: Female / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Histone Deacetylase Inhibitors / Hydroxamic Acids Limits: Female / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article